for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akari Therapeutics PLC (ADR)

AKTX.OQ

Latest Trade

1.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.56

 - 

9.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Akari Therapeutics Reports Third Quarter 2019 Financial Results

Nov 4 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF SEPTEMBER 30, 2019, COMPANY HAD CASH OF $6.3 MILLION.AKARI THERAPEUTICS - CLINICAL TRIAL FOR PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY EXPECTED TO START Q4 2019.AKARI THERAPEUTICS - ENROLLMENT IN PART B PLACEBO-CONTROLLED EFFICACY ARM OF STUDY IN 16 PATIENTS CONTINUES, WITH A DATA READ OUT EXPECTED IN Q1 OF 2020.AKARI THERAPEUTICS PLC - PIVOTAL TRIAL FOR HSCT-TMA WITH NOMACOPAN IS EXPECTED TO START IN Q4 OF 2019.AKARI THERAPEUTICS PLC - ONGOING PHASE III PNH STUDY IN NAÏVE PATIENTS IS EXPECTED TO HAVE AN INTERIM DATA READOUT IN MID 2020.

Akari Therapeutics Files Prospectus Related To Sale Of Up To 520 Mln Of Ordinary Shares By Aspire Capital Fund

Oct 15 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS FILES PROSPECTUS RELATED TO SALE OF UP TO 520 MILLION OF ORDINARY SHARES BY ASPIRE CAPITAL FUND LLC - SEC FILING.

Akari Therapeutics Announces New Data From Atopic Keratoconjunctivitis (Akc) Patients Supporting The Potentially Beneficial Role Of Nomacopan As An Inhibitor Of Both C5 And LTB4 In The Ongoing P

Oct 14 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS ANNOUNCES NEW DATA FROM ATOPIC KERATOCONJUNCTIVITIS (AKC) PATIENTS SUPPORTING THE POTENTIALLY BENEFICIAL ROLE OF NOMACOPAN AS AN INHIBITOR OF BOTH C5 AND LTB4 IN THE ONGOING PHASE I/II AKC TRIAL.AKARI THERAPEUTICS PLC - CO'S PHASE I/II CLINICAL TRIAL OF TOPICAL NOMACOPAN IN AKC IS ONGOING & AN INTERIM DATA READOUT IS EXPECTED AT END 2019.

Akari Therapeutics Announces Positive Phase II Clinical Data In Orphan Blistering Skin Disease Bullous Pemphigoid

Oct 10 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS ANNOUNCES POSITIVE PHASE II CLINICAL DATA IN ORPHAN BLISTERING SKIN DISEASE BULLOUS PEMPHIGOID AT THE 28TH EADV CONGRESS.AKARI THERAPEUTICS PLC - NO REPORTED DRUG-RELATED SERIOUS ADVERSE EVENTS.AKARI THERAPEUTICS PLC - TREATMENT WITH NOMACOPAN IN SIX PATIENTS IN PHASE II TRIAL WAS WELL TOLERATED.AKARI THERAPEUTICS - INTENDS TO PRESENT NEW PHASE II DATA TO U.S. FDA AND EMA TO ADVANCE POTENTIAL PIVOTAL TRIAL DESIGN FOR PATIENTS WITH BP.AKARI THERAPEUTICS PLC - TREATMENT WITH NOMACOPAN RESULTED IN RAPID ONSET OF CLINICAL IMPROVEMENT IN FIVE OF SIX PATIENTS.AKARI THERAPEUTICS PLC - INTEND TO BEGIN PIVOTAL STUDY OF NOMACOPAN IN H2 2020.

Akari Therapeutics Reports Qtrly Loss Per Share $0.00

Aug 29 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - CLIVE RICHARDSON HAS BEEN APPOINTED PERMANENT CEO OF CO.AKARI THERAPEUTICS PLC - AS OF JUNE 30, 2019, CO HAD CASH OF $2.7 MILLION.AKARI THERAPEUTICS PLC - FURTHER CLINICAL DATA FROM BP AND AKC TRIALS ANTICIPATED Q4 2019.AKARI THERAPEUTICS - CLINICAL TRIAL FOR PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY EXPECTED TO START Q4 2019.

Akari Therapeutics Receives FDA's "Fast Track" Status For Nomacopan

Aug 14 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR NOMACOPAN FOR PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).AKARI THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR NOMACOPAN FOR PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).AKARI THERAPEUTICS PLC - PROPOSED PIVOTAL TRIAL OF NOMACOPAN IN PEDIATRIC PATIENTS WITH HSCT-TMA EXPECTED TO START Q4 2019 IN NORTH AMERICA AND EUROPE.

Akari Therapeutics Announces New Data Demonstrating Synergistic Benefits Of Nomacopan’s Bifunctional C5 And LTB4 Inhibitory Activity In Pemphigoid Disease

Aug 9 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS ANNOUNCES NEW DATA DEMONSTRATING SYNERGISTIC BENEFITS OF NOMACOPAN’S BIFUNCTIONAL C5 AND LTB4 INHIBITORY ACTIVITY IN PEMPHIGOID DISEASE.AKARI THERAPEUTICS PLC - DATA SUPPORT POTENTIAL THERAPEUTIC ROLE OF NOMACOPAN FOR TREATMENT OF BP WHICH IS BEING EVALUATED IN AKARI'S CURRENT PHASE II CLINICAL TRIAL IN PATIENTS WITH BP.AKARI THERAPEUTICS PLC - THERE WERE NO REPORTED DRUG RELATED SERIOUS ADVERSE EVENTS FOR BP PATIENTS.

Akari Therapeutics Files Prospectus Relates To Resale, By Selling Shareholders Of Up To 136.2 Mln Ordinary Shares

Aug 6 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS PLC FILES PROSPECTUS RELATES TO RESALE, BY SELLING SHAREHOLDERS OF UP TO AN AGGREGATE OF 136.2 MILLION ORDINARY SHARES - SEC FILING.

Akari Therapeutics Qtrly Loss Per Share $0.00

May 29 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC - FURTHER CLINICAL DATA FROM BP AND AKC TRIALS ANTICIPATED IN 2019.AKARI THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF MARCH 30, 2019, COMPANY HAD CASH OF $6.1 MILLION, AS COMPARED TO CASH OF $5.4 MILLION AS OF DECEMBER 31, 2018.

Akari QTRLY Loss Per Share $0.00

April 23 (Reuters) - Akari Therapeutics PLC <AKTX.O>::AKARI REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKARI THERAPEUTICS PLC QTRLY LOSS PER SHARE $0.00.AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $5.4 MILLION, AS COMPARED TO CASH OF $28.1 MILLION AS OF DECEMBER 31, 2017.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up